Alnylam Pharmaceuticals Inc experienced a price decline of 3.03%, hitting a 20-day low amid broader market trends. The Nasdaq-100 and S&P 500 indices showed slight gains, indicating a disconnect between Alnylam's performance and the overall market.
Recent board changes at Alnylam, including the appointment of Stuart Arbuckle as a new independent director, aim to enhance the company's strategic direction and growth potential in RNAi therapeutics. However, these changes have not yet translated into positive market sentiment for the stock.
Investors are closely monitoring Alnylam's developments as the company continues to navigate its pipeline of products. The current market conditions may pose challenges, but the strategic shifts within the company could provide future opportunities for recovery.
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 500.28 USD with a low forecast of 351.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 500.28 USD with a low forecast of 351.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 349.580
Low
351.00
Averages
500.28
High
570.00
Current: 349.580
Low
351.00
Averages
500.28
High
570.00
Barclays
Eliana Merle
initiated
$527
2026-01-27
New
Reason
Barclays
Eliana Merle
Price Target
$527
AI Analysis
2026-01-27
New
initiated
Reason
Barclays analyst Eliana Merle assumed coverage of Alnylam with an Overweight rating and $527 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
RBC Capital
Outperform
maintain
$500 -> $465
2026-01-20
Reason
RBC Capital
Price Target
$500 -> $465
2026-01-20
maintain
Outperform
Reason
RBC Capital lowered the firm's price target on Alnylam to $465 from $500 but keeps an Outperform rating on the shares after meeting with its management team following its FY26 net product revenue outlook. On Amvuttra, the company clarified that the soft November was driven by a few one-offs and highlighted a "very impressive December", the analyst tells investors in a research note. On 2026, Alnylam announced a splashy guide, primarily driven by TTR - transthyretin amyloidosis, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALNY
Unlock Now
Wells Fargo
Equal Weight
downgrade
$479 -> $376
2026-01-20
Reason
Wells Fargo
Price Target
$479 -> $376
2026-01-20
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Alnylam to $376 from $479 and keeps an Equal Weight rating on the shares. The firm raised FY26 Amvuttra estimates by 6% but its R&D expenses move up to about 30% of revenues between 2026-2030, compressing operating margins to management's 30% guide vs. Street's 40%-50%.
Truist
Buy
downgrade
$535 -> $530
2026-01-08
Reason
Truist
Price Target
$535 -> $530
2026-01-08
downgrade
Buy
Reason
Truist lowered the firm's price target on Alnylam to $530 from $535 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
